FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126759970> ?p ?o ?g. }

• W3126759970 endingPage "894" @default.
• W3126759970 startingPage "893" @default.
• W3126759970 abstract "We recently published a paper in Molecular Therapy that studies the impact of corticosteroids and cellulose-based purification on the innate immunity, translation, and efficacy of self-amplifying mRNA (sa-mRNA) vaccines.1Zhong Z. Mc Cafferty S.M. Opsomer L. Wang H. Huysmans H. De Temmerman J. et al.Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs.Mol. Ther. 2021; (Published online January 20, 2021)https://doi.org/10.1016/j.ymthe.2021.01.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar With this Letter to the Editor, we want to highlight the relevance of a particular subset of data for the ongoing mRNA vaccination campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In our work, we demonstrated in mice that a short course of dexamethasone, hydrocortisone, or clobetasol significantly reduced the type I interferon (IFN) responses and improved the in vivo translation of sa-mRNA vaccines.1Zhong Z. Mc Cafferty S.M. Opsomer L. Wang H. Huysmans H. De Temmerman J. et al.Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs.Mol. Ther. 2021; (Published online January 20, 2021)https://doi.org/10.1016/j.ymthe.2021.01.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar This is an important observation because it might bring sa-mRNAs for protein (replacement) therapies closer to the clinic. Corticosteroids are also used to suppress immune reactions against Luxturna, an approved adeno-associated virus-based gene therapy for retinal dystrophy. However, for mRNA vaccines, the elicited type I IFN response is considered beneficial because it results in the release of cytokines that shape and promote the adaptive immune responses.2Linares-Fernández S. Lacroix C. Exposito J.Y. Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.Trends Mol. Med. 2020; 26: 311-323Abstract Full Text Full Text PDF PubMed Scopus (54) Google Scholar, 3Deering R.P. Kommareddy S. Ulmer J.B. Brito L.A. Geall A.J. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.Expert Opin. Drug Deliv. 2014; 11: 885-899Crossref PubMed Scopus (97) Google Scholar, 4Zhong Z. Mc Cafferty S. Combes F. Huysmans H. De Temmerman J. Gitsels A. Vanrompay D. Portela Catani J. Sanders N.N. mRNA therapeutics deliver a hopeful message.Nano Today. 2018; 23: 16-39Crossref Scopus (58) Google Scholar Nevertheless, a too-strong type I IFN response is known to impede mRNA translation and inhibit the adaptive immune response.5Van Hoecke L. Roose K. Ballegeer M. Zhong Z. Sanders N.N. De Koker S. Saelens X. Van Lint S. The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration.Mol. Ther. Nucleic Acids. 2020; 22: 373-381Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar, 6Zhong Z. Portela Catani J.P. Mc Cafferty S. Couck L. Van Den Broeck W. Gorlé N. Vandenbroucke R.E. Devriendt B. Ulbert S. Cnops L. et al.Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine.Vaccines (Basel). 2019; 7: 96Crossref PubMed Scopus (16) Google Scholar, 7De Beuckelaer A. Pollard C. Van Lint S. Roose K. Van Hoecke L. Naessens T. Udhayakumar V.K. Smet M. Sanders N. Lienenklaus S. et al.Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.Mol. Ther. 2016; 24: 2012-2020Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar To maximize the efficacy of mRNA vaccines, it seems that a well-balanced type I IFN response is required. Therefore, we wondered whether this balance could be disturbed when mRNA vaccines were combined with corticosteroids. Surprisingly, a short course of topical clobetasol at the vaccination site completely blunted the humoral (antibody) response elicited by a sa-mRNA vaccine against Zika virus (ZIKVac-sa-mRNA vaccine). In addition, topical hydrocortisone and oral dexamethasone demonstrated a comparable decrease in type I IFN response at the injection site.1Zhong Z. Mc Cafferty S.M. Opsomer L. Wang H. Huysmans H. De Temmerman J. et al.Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs.Mol. Ther. 2021; (Published online January 20, 2021)https://doi.org/10.1016/j.ymthe.2021.01.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar Therefore, a similar inhibitory effect on the efficacy of mRNA vaccines is expected with oral dexamethasone and topical hydrocortisone. More evidence for the devastating effects of corticosteroids on mRNA vaccines comes from the work of Vormehr et al.8Vormehr M. Lehar S. Kranz L.M. Tahtinen S. Oei Y. Javinal V. Delamarre L. Walzer K.C. Diken M. Kreiter S. et al.Dexamethasone premedication suppresses vaccine-induced immune responses against cancer.OncoImmunology. 2020; 9: 1758004Crossref PubMed Scopus (10) Google Scholar These authors found that the number of antigen-specific T cells elicited by an mRNA cancer vaccine was significantly lower if the mice received intraperitoneal dexamethasone 3 h before vaccination. Even more alarming is the observation that their mRNA vaccine started to induce regulatory T cells (Tregs) when combined with dexamethasone. The latter may indicate that immune tolerance is lurking around the corner when mRNA vaccines are given together with certain corticosteroids. In our study, we administered the sa-mRNA vaccine intradermally using electroporation, while Vormehr et al.8Vormehr M. Lehar S. Kranz L.M. Tahtinen S. Oei Y. Javinal V. Delamarre L. Walzer K.C. Diken M. Kreiter S. et al.Dexamethasone premedication suppresses vaccine-induced immune responses against cancer.OncoImmunology. 2020; 9: 1758004Crossref PubMed Scopus (10) Google Scholar gave their lipid formulated mRNA vaccine intravenously. Both studies were performed in mice. The current coronavirus disease 2019 (COVID-19) mRNA vaccines are formulated in lipid nanoparticles and given intramuscularly.9Polack F.P. Thomas S.J. Kitchin N. Absalon J. Gurtman A. Lockhart S. Perez J.L. Pérez Marc G. Moreira E.D. Zerbini C. et al.C4591001 Clinical Trial GroupSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.N. Engl. J. Med. 2020; 383: 2603-2615Crossref PubMed Scopus (3758) Google Scholar,10Baden L.R. El Sahly H.M. Essink B. Kotloff K. Frey S. Novak R. Diemert D. Spector S.A. Rouphael N. Creech C.B. et al.COVE Study GroupEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.N. Engl. J. Med. 2020; https://doi.org/10.1056/NEJMoa2035389Crossref Scopus (2383) Google Scholar Despite these differences, it is still very plausible that the vaccination efficacy of the mRNA vaccines against SARS-CoV-2 will also be decreased in patients treated with corticosteroids. Consequently, the immunogenicity and protection efficacy of the SARS-CoV-2 mRNA vaccines in patients who concurrently receive corticosteroids must be urgently investigated. In the meantime, we should consider postponing COVID-19 mRNA vaccination in patients currently receiving high doses of corticosteroids. Corticosteroids induce immunosuppression by interfering with the signaling of nuclear factor κB (NF-κB) and activator protein 1 (AP-1), which results in a decreased expression of pro-inflammatory cytokines and chemokines.11Coutinho A.E. Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.Mol. Cell. Endocrinol. 2011; 335: 2-13Crossref PubMed Scopus (812) Google Scholar Moreover, corticosteroids are widely used for acute and chronic inflammations, including severe allergies, asthma, rheumatoid arthritis, inflammatory bowel diseases, skin diseases, and multiple sclerosis.11Coutinho A.E. Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.Mol. Cell. Endocrinol. 2011; 335: 2-13Crossref PubMed Scopus (812) Google Scholar For example, in the UK, 1% of the total adult population and 2.5% of the elderly between 70 and 79 years of age took oral corticosteroids in the year 2000.12van Staa T.P. Leufkens H.G. Abenhaim L. Begaud B. Zhang B. Cooper C. Use of oral corticosteroids in the United Kingdom.QJM. 2000; 93: 105-111Crossref PubMed Scopus (386) Google Scholar Finally, it is possible that other immune suppressive drugs, such as cyclosporine and methotrexate, could also prove detrimental to the vaccination efficacy of mRNA vaccines." @default.
• W3126759970 created "2021-02-15" @default.
• W3126759970 creator A5024365503 @default.
• W3126759970 creator A5024611033 @default.
• W3126759970 creator A5048595477 @default.
• W3126759970 date "2021-03-01" @default.
• W3126759970 modified "2023-10-16" @default.
• W3126759970 title "Corticosteroids and mRNA Vaccines: A Word of Caution" @default.
• W3126759970 cites W2013980575 @default.
• W3126759970 cites W2070751802 @default.
• W3126759970 cites W2185954894 @default.
• W3126759970 cites W2484775100 @default.
• W3126759970 cites W2901779366 @default.
• W3126759970 cites W2969386184 @default.
• W3126759970 cites W2986812831 @default.
• W3126759970 cites W3025595789 @default.
• W3126759970 cites W3085627131 @default.
• W3126759970 cites W3111255098 @default.
• W3126759970 cites W3123562152 @default.
• W3126759970 cites W4205483821 @default.
• W3126759970 doi "https://doi.org/10.1016/j.ymthe.2021.01.029" @default.
• W3126759970 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7934628" @default.
• W3126759970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33549165" @default.
• W3126759970 hasPublicationYear "2021" @default.
• W3126759970 type Work @default.
• W3126759970 sameAs 3126759970 @default.
• W3126759970 citedByCount "1" @default.
• W3126759970 countsByYear W31267599702022 @default.
• W3126759970 crossrefType "journal-article" @default.
• W3126759970 hasAuthorship W3126759970A5024365503 @default.
• W3126759970 hasAuthorship W3126759970A5024611033 @default.
• W3126759970 hasAuthorship W3126759970A5048595477 @default.
• W3126759970 hasBestOaLocation W31267599701 @default.
• W3126759970 hasConcept C104317684 @default.
• W3126759970 hasConcept C105580179 @default.
• W3126759970 hasConcept C138885662 @default.
• W3126759970 hasConcept C159047783 @default.
• W3126759970 hasConcept C41895202 @default.
• W3126759970 hasConcept C54355233 @default.
• W3126759970 hasConcept C71924100 @default.
• W3126759970 hasConcept C86803240 @default.
• W3126759970 hasConcept C90805587 @default.
• W3126759970 hasConceptScore W3126759970C104317684 @default.
• W3126759970 hasConceptScore W3126759970C105580179 @default.
• W3126759970 hasConceptScore W3126759970C138885662 @default.
• W3126759970 hasConceptScore W3126759970C159047783 @default.
• W3126759970 hasConceptScore W3126759970C41895202 @default.
• W3126759970 hasConceptScore W3126759970C54355233 @default.
• W3126759970 hasConceptScore W3126759970C71924100 @default.
• W3126759970 hasConceptScore W3126759970C86803240 @default.
• W3126759970 hasConceptScore W3126759970C90805587 @default.
• W3126759970 hasFunder F4320321730 @default.
• W3126759970 hasFunder F4320322603 @default.
• W3126759970 hasFunder F4320322725 @default.
• W3126759970 hasIssue "3" @default.
• W3126759970 hasLocation W31267599701 @default.
• W3126759970 hasLocation W31267599702 @default.
• W3126759970 hasLocation W31267599703 @default.
• W3126759970 hasOpenAccess W3126759970 @default.
• W3126759970 hasPrimaryLocation W31267599701 @default.
• W3126759970 hasRelatedWork W1702322095 @default.
• W3126759970 hasRelatedWork W1848848102 @default.
• W3126759970 hasRelatedWork W1865764402 @default.
• W3126759970 hasRelatedWork W1975114493 @default.
• W3126759970 hasRelatedWork W2118087741 @default.
• W3126759970 hasRelatedWork W2372082059 @default.
• W3126759970 hasRelatedWork W2748952813 @default.
• W3126759970 hasRelatedWork W2899084033 @default.
• W3126759970 hasRelatedWork W3029386773 @default.
• W3126759970 hasRelatedWork W4304606192 @default.
• W3126759970 hasVolume "29" @default.
• W3126759970 isParatext "false" @default.
• W3126759970 isRetracted "false" @default.
• W3126759970 magId "3126759970" @default.
• W3126759970 workType "article" @default.